NewsDesk @bactiman63

In a follow-up on the Carbapenemase-producing organisms (CPO) detected in Denmark, the Statens Serum Institut (SSI) has detected two more cases of multi-resistant bacteria in patients who have been treated with the drug Dicillin.

Carbapenem-resistant Enterobacteriaceae/CDC

In addition, traces of the special multiresistant CPO bacterium have been found in a further 12 patients, of whom it has been confirmed that eight have been treated with Dicillin in the period before the discovery. The remaining four cases are still being investigated.

Thus, the outbreak with the bacterial strain now includes a total of 25 cases, as 11 cases had previously been identified.

The case of the multi-resistant bacteria and the drug Dicillin began when, in October 2022, the SSI registered an increase in a special multi-resistant CPO bacterium that had not been seen before. On closer examination, the increase in bacteria could not be related to infection in hospitals or travel abroad, but was detected last month on the surface of capsules of the medicine Dicillin. It also turned out that all the patients had taken the medicine up to the detection of the bacteria.

SSI is following the outbreak closely and the Danish Medicines Agency is working with the manufacturer to uncover the causes of the outbreak.

None of the Danish patients have become seriously ill from the bacteria, just as it has not been necessary to initiate other treatment for the bacteria.

Subscribe to Outbreak News TV on YouTube

“This is not something that is dangerous for the individual patient, but we must of course do what we can to avoid the spread of multi-resistant bacteria”, professional director at SSI, Tyra Grove Krause. says and continues:

“We know that most CPO bacteria have the ability to share their resistance with other bacterial species, so that part is not so surprising”.